SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-14-189017
Filing Date
2014-05-08
Accepted
2014-05-08 09:22:00
Documents
5
Period of Report
2014-05-08
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d722587d8k.htm 8-K 18733
2 EX-99.1 d722587dex991.htm EX-99.1 137958
3 EX-99.2 d722587dex992.htm EX-99.2 10246
4 GRAPHIC g722587ex99_1logo.jpg GRAPHIC 8155
5 GRAPHIC g722587ex99_1s1gbgd.jpg GRAPHIC 55443
  Complete submission text file 0001193125-14-189017.txt   256172
Mailing Address 15 NEW ENGLAND EXECUTIVE PARK BURLINGTON MA 01803
Business Address 15 NEW ENGLAND EXECUTIVE PARK BURLINGTON MA 01803 617-513-9882
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 14823265
SIC: 2834 Pharmaceutical Preparations